CD8A and neoplasm: Adoptive T cell therapy with cells expanded from PD-1+CD8+ tumor-infiltrating lymphocytes (TILs), but not from PD-1− or bulk CD8+ TILs, showed tumor-reactivity and therapeutic benefit in vivo (15).